The U.S. authorities’s reliance on the most-favored-nation (MFN) pricing mannequin — tying drug prices to the bottom value paid by different international locations — is a politically interesting however structurally flawed answer.
At first look, pegging U.S. drug costs to these in different rich international locations seems like widespread sense. However the MFN method invitations critical authorized, financial, and moral problems. It might disrupt international entry, deter innovation, and obscure the deeper systemic points in American well being care.
America has lengthy paid considerably extra for a similar prescription drugs than different high-income international locations, elevating persistent considerations about worldwide value disparities. On Could 12, 2025, President Donald Trump signed Govt Order 14,297, directing the adoption of an MFN pricing mannequin for prescribed drugs. Beneath this coverage, drugmakers should match or beat the bottom value paid by international locations akin to Canada, Germany, or France, or face regulatory penalties. However whereas it guarantees short-term financial savings for U.S. sufferers, the long-term results could possibly be legally fraught and globally destabilizing.
This isn’t Trump’s first try at MFN-style pricing; an analogous govt order was issued in 2020, although it confronted authorized pushback and was by no means totally carried out. Different international locations use reference pricing too, however many of the high-income international locations usually use centralized or public-oriented well being methods that make it possible.
Authorized and Commerce Implications
Tying drug costs to worldwide benchmarks opens the U.S. to accusations of coercive commerce practices. Nations whose low costs are used as baselines might face diplomatic strain to boost them — particularly if American pharmaceutical corporations start lobbying for tariffs or regulatory retaliation. This poses a danger of inciting commerce disputes, doubtlessly contravening World Commerce Group (WTO), significantly below the Settlement on Commerce-Associated Features of Mental Property Rights (TRIPS), which protects pharmaceutical patents and market-based pricing.
Pharmaceutical corporations may additionally problem MFN pricing domestically, citing due course of considerations and even alleging uncompensated takings of their IP worth. Already, President Trump’s 2020 model of the MFN rule confronted a number of authorized challenges that stalled implementation. Furthermore, MFN pricing successfully imports the value management mechanisms of overseas international locations with out adopting their broader well being system constructions. This selective method is economically incoherent and legally weak, as drugmakers argue U.S. regulation doesn’t allow utilizing overseas value references with out correct evaluation or safeguards.
World Well being Fairness and Patent System Abuse
If pharmaceutical corporations are pressured to simply accept decrease earnings within the U.S., they might attempt to compensate by elevating costs in markets that presently profit from lower-cost medication — significantly in Europe and components of the World South. This undermines international well being fairness, as international locations with common well being care methods or restricted budgets might see diminished entry. In essence, the U.S. can be exporting its high-cost mannequin, doubtlessly turning an American pricing reform into a world affordability disaster.
MFN pricing does little to repair the structural drivers of inflated drug prices within the U.S. — most notably, patent system abuse. Pharmaceutical corporations routinely exploit the U.S. patent regime to increase exclusivity intervals via minor modifications to present medication (so-called “evergreening”). This apply delays the entry of generics and biosimilars, holding costs artificially excessive for customers and payers.
In contrast to many peer international locations, the U.S. lacks strict patent linkage evaluations or centralized pricing commissions that consider therapeutic worth. Consequently, producers can preserve monopolies for many years, whereas providing marginal scientific enhancements at premium costs. MFN pricing might decrease the reimbursement ceiling, however it doesn’t problem this underlying enterprise mannequin … one which thrives on regulatory fragmentation and patent stacking.
Innovation-Chilling Impact
Proponents of MFN typically downplay its affect on innovation, however the economics are unavoidable. Pharmaceutical R&D is high-risk, capital-intensive, and largely profit-driven. If revenues shrink sharply within the U.S. (presently the world’s most profitable drug market), corporations might delay or cut back funding in new remedies. The menace isn’t speedy, however over time, diminished profitability can shift priorities away from growing breakthrough therapies, particularly for uncommon illnesses or situations affecting smaller populations.
When Pfizer-BioNTech grew to become the primary to launch a breakthrough COVID-19 vaccine in late 2020, the U.S. paid roughly $19.50 per dose — as much as 40 p.c greater than some European international locations. That premium pricing helped safe early entry and mass rollout, a transparent case the place excessive costs arguably supported speedy innovation and deployment. If MFN pricing forces corporations to cost U.S. sufferers the identical as international locations with centralized value controls, the motivation to prioritize U.S. distribution — or to take a position closely in future breakthrough therapies — might erode. Over time, this may occasionally delay medical advances, particularly for high-risk or low-demand remedies.
Structural Evasion, Not Reform
Most troubling is that MFN pricing skirts round the actual drivers of inflated U.S. drug prices. Pharmacy Profit Managers (PBMs), who act as middlemen between drugmakers and insurers, typically negotiate secretive rebates and costs that obscure true pricing. Medicare, the most important authorities payer, nonetheless lacks full authority to barter instantly with drug producers. And U.S. patent regulation permits extreme extensions that delay generics from getting into the market. MFN pricing doesn’t repair these systemic failures — it merely masks them by borrowing costs from overseas.
By counting on overseas value controls as a substitute of reforming its personal provide chain, the U.S. dangers short-term political wins on the expense of long-term international stability and home transparency.
Conclusion: Actual Reform Requires Structural Change
MFN pricing is a shortcut masquerading as an answer. It borrows overseas costs with out replicating the clear, centralized methods that make these costs sustainable. Extra importantly, it fails to confront the core points inflating U.S. drug prices: patent system manipulation, PBM opacity, and Medicare’s restricted negotiating energy.
To create lasting change, the U.S. should:
- empower Medicare to barter instantly with drug producers;
- reform patent regulation to shut evergreening loopholes and shorten exclusivity intervals;
- enhance transparency in PBM contracts and rebate schemes; and
- assist generic and biosimilar competitors via energetic coverage incentives.
Solely then can we construct a system that promotes affordability with out undermining fairness or innovation — at residence or overseas.
Concerning the writer
Ganeswar Matcha is Managing Director at Sacha Group LLC and a authorized researcher in worldwide environmental and well being regulation. He holds an LL.M. from American College Washington School of Legislation, and his work spans pharmaceutical commerce, local weather coverage and maritime governance.